Abiopharma

🔍 Armes Joseph B (Director)

Company: CSW INDUSTRIALS, INC. (CSW)

Report Date: 2026-04-26

Detailed Transactions and Holdings:

• Sold 12,394 shares of Common Stock at $296.18 per share (Direct)
  Date: 2026-04-26 | Code: F | equity_swap_involved: 0 | shares_owned_after: 72,100.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-26 | Code: H | nature_of_ownership: by ESOP | shares_owned_after: 3,219.00
• Holds 8,004 shares of Performance Rights (Derivative)
  Date: 2026-04-26 | Code: H | shares_owned_after: 8,004.00 | Footnotes: F1, F1, F1
• Holds 8,236 shares of Performance Rights (Derivative)
  Date: 2026-04-26 | Code: H | shares_owned_after: 8,236.00 | Footnotes: F2, F2, F2
• Holds 9,186 shares of Performance Rights (Derivative)
  Date: 2026-04-26 | Code: H | shares_owned_after: 9,186.00 | Footnotes: F3, F3, F3
• Holds 19,685 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-26 | Code: H | shares_owned_after: 19,685.00 | Footnotes: F4, F4, F4

Footnotes:

• F1: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2025, and ending on March 31, 2028, based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
• F2: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2024, and ending on March 31, 2027, based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
• F3: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200%, during a performance cycle beginning April 1, 2021 and ending on March 31, 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
• F4: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at vesting. 40% of the restricted stock units vest no earlier than April 26, 2025 upon the successful recruitment and hiring of a successor Chief Executive Officer; the remaining 60% vest upon the successful first employment anniversary of a successor Chief Executive Officer.